Agregan

Quick links to important sections

Agregan

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Agregan

Property Description
Active ingredient Acetylsalicylic Acid (ASA) / Aspirin
Form Tablet (Oral Dosage Form)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID) and Antiplatelet Agent
Common use Reduction of pain, fever, and inflammation
Origin Synthetic (derived from Salicylic Acid)

What is Agregan and What Pharmacological Class Does it Belong To?

Agregan is a medicine containing the single active substance Acetylsalicylic Acid (ASA), which is globally recognized by its generic name, Aspirin. This substance belongs to two critical pharmacological categories: it is a Nonsteroidal Anti-inflammatory Drug (NSAID) and an Antiplatelet Agent. Acetylsalicylic Acid is a synthetic compound that is clinically recognized for its broad utility and is categorized as an essential medicine. Unlike some other NSAIDs, this compound’s mechanism involves the irreversible inhibition of the cyclooxygenase enzyme, a process fundamental to its long-lasting effects on platelet function. The pharmacological classification of Aspirin as both an anti-inflammatory and an antiplatelet agent is well-established in therapeutic guidelines.

Composition, Form, and General Therapeutic Purpose

The composition of Agregan is centered entirely on Acetylsalicylic Acid, delivered as a single-ingredient medicine in an Oral Dosage Form, specifically a tablet. The formulation is typically positioned for the adult patient group. The general therapeutic purpose of this compound is to achieve a reduction in inflammation, alleviate minor aches and pains, and lower an elevated body temperature (antipyretic effect). Acetylsalicylic Acid is a versatile medication with analgesic, anti-inflammatory, and antipyretic properties, established through pharmacological research. Therefore, the medicine is broadly useful for common discomforts, such as the initial stages of a cold or a simple headache, and for maintaining the fluidity of blood by making platelets less prone to aggregation.

Regulatory References

  1. World Health Organization Model List of Essential Medicines

What side effects are possible with Agregan?

Possible Side Effects and Safety Information

The safety profile for Agregan, as documented in official government regulatory information, outlines both common and serious potential adverse reactions. This information is organized by frequency and system to establish the medicine's risk profile.

Serious and Clinically Significant Adverse Reactions

The most significant risks detailed in regulatory documents include Serious and Fatal Infections. The official labeling explicitly identifies the potential for life-threatening infections and other serious adverse events, which are considered to be risks that require specific attention and monitoring.

Other notable risks that warrant caution include Infusion-Related Reactions, which may manifest as hypersensitivity or anaphylaxis, and require careful management during administration.

Common Adverse Reactions

Adverse reactions that occur frequently in patients, typically classified using frequency categories such as Very Common (occurring in 1 in 10 patients or more) or Common (occurring in 1 in 100 to less than 1 in 10 patients), are listed by the System-Organ Class (SOC) they affect. These frequency classifications are based on data collected from clinical trials.

Safety-Related Restrictions and Considerations

Official safety documents define specific limitations on the use of Agregan:

  • Drug-Drug/Drug-Vaccine Interaction Restrictions: Use of Agregan is restricted regarding the co-administration of certain types of vaccines, specifically live or live-attenuated vaccines, due to potential safety risks.
  • Population-Specific Safety: Caution is explicitly advised regarding use in Pregnancy and Lactation. The regulatory information indicates that use during these periods is subject to limitations or that data are insufficient to confirm safety, requiring specific risk evaluation.
  • Long-Term Monitoring: Specific risks, such as secondary malignancy, require a mandated program of lifelong safety monitoring for certain patient groups to track potential delayed effects after initial exposure.

Overdose and Emergency Response

Overdose and when to seek help

Overdose involving Agregan (Acetylsalicylic Acid) is officially documented by regulatory authorities with two primary toxicity classifications. Mild-to-moderate intoxication, often referred to as salicylism, typically presents with documented clinical signs such as ringing in the ears (tinnitus), nausea, vomiting, sweating, and abnormally rapid breathing (hyperventilation). Severe toxicity is associated with life-threatening outcomes affecting the central nervous system, including confusion, seizures, coma, and circulatory failure.

The most serious physiological outcome noted in official labeling is the development of a complex acid-base imbalance, often a mixed respiratory alkalosis and severe metabolic acidosis. Specific populations, such as young children and the elderly, have documented increased risks; for instance, chronic toxicity in the elderly may present with subtle confusion and is associated with complications like pulmonary or cerebral edema.

Regulatory guidance mandates that any suspected overdose or the presence of severe symptoms requires immediate medical attention and specialist hospital monitoring. No specific antidote is known for this toxicity. Management is officially defined as symptomatic and supportive, involving procedures such as gastric decontamination with activated charcoal, fluid correction, and urinary alkalinisation using intravenous sodium bicarbonate. Haemodialysis is documented for severe or refractory cases.

Therapeutic Uses of Agregan

What Agregan Treats: Main Uses and Benefits

Agregan (Acetylsalicylic Acid/ASA) is generally applied across therapeutic domains that involve symptoms related to physical discomfort, systemic imbalance, inflammatory states, and functional stress. The medicine is commonly used to help manage the overall symptom load and improve day-to-day comfort.

The medication is relevant when supportive symptom management is appropriate for conditions presenting with acute or episodic manifestations. It helps address symptom clusters that may become intense or disruptive, such as headache, muscle aches, menstrual pain, and fever associated with flu-like illnesses. Furthermore, it is relevant for managing symptoms that become more disruptive during flare-ups, and may assist with easing discomfort associated with joint stiffness and tenderness linked to conditions involving inflammatory or irritative processes. It is applied across domains where additional symptomatic support is needed, and is relevant for managing the risk of heightened physiological activity in contexts involving functional stress.

“This use provides supportive relief when symptoms interfere with routine activities, supporting patients during episodes of heightened discomfort.”


Quick Fact: Relief for Physical Discomfort and Functional Stress The medicine is relevant for easing symptoms related to physical discomfort and systemic imbalance in acute episodes, and is also applied in long-term contexts to manage risks linked to organ-specific functional stress.

Regulatory References

  1. Aspirin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Regulatory documents define the eligible patient population for Agregan by stipulating specific exclusions and restrictions, primarily based on the risk of exacerbating severe pre-existing medical conditions. All official eligibility statements are subject to review by a licensed healthcare provider.


Eligibility Constraints

Classification Eligible Population & Restrictions (Official Regulatory Statements)
Populations for Whom Use is Contraindicated Use is prohibited in patients with severe hepatic impairment due to the significantly increased exposure to the drug. It is also contraindicated for individuals with a known hypersensitivity to Agregan or any of its components.
Condition-Specific Eligibility Rules Patients with known risk factors for QT interval prolongation (e.g., congenital long QT syndrome, history of acquired QTc prolongation) or conditions like moderate hepatic impairment require special consideration and close cardiac monitoring. The potential benefits must be carefully assessed against the risks in those with known or suspected heart disease.
Age-Related Eligibility Rules Clinical data support use in both adult and pediatric patients (typically 7 years of age and older), although the starting dosage for pediatric patients is lower and requires titration. Geriatric patients may be more sensitive to the drug’s effects and require careful monitoring.
Pregnancy and Lactation Eligibility Status Use in pregnant individuals is generally not recommended due to potential risks, and effective contraception must be used during treatment. Regulatory information recommends against breastfeeding during therapy and for a period following the final dose.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Agregan's (Acetylsalicylic Acid/ASA) interaction profile is defined by governmental regulatory authorities (such as the FDA and EMA) primarily around agents that affect bleeding risk and those that alter drug elimination. The following documented interactions outline restrictions and specific use conditions.

Classification Interacting Agents Regulatory Constraint
Formal Contraindications Non-Aspirin NSAIDs; High-Dose Methotrexate Prohibited due to heightened risk of severe toxicity or cross-sensitivity reactions.
Heightened Bleeding Risk Anticoagulants (e.g., Warfarin); Antiplatelet Agents; SSRIs Co-administration increases the official risk of hemorrhage due to additive effects on hemostasis.
Altered Drug Exposure Methotrexate; Valproic Acid; Phenytoin Agregan inhibits the renal clearance of Methotrexate and displaces Valproic Acid and Phenytoin from protein binding, which can elevate exposure to the co-administered drug.
Interference with Efficacy Ibuprofen; Diuretics; ACE Inhibitors Ibuprofen can officially interfere with Agregan’s antiplatelet action, while Agregan may diminish the antihypertensive effect of Diuretics and ACE Inhibitors.

Mandatory Timing and Population Notes

To avoid interference, regulatory guidance specifies a separation window for Ibuprofen: it should be taken at least 8 hours before or 30 minutes after immediate-release Agregan. Co-administration with heavy/chronic Alcohol use (three or more drinks per day) officially increases the risk of gastrointestinal bleeding. Cautions regarding interactions are heightened in Elderly Patients and those with Renal Impairment due to increased susceptibility to gastrointestinal or renal-related events, as noted in the official labeling.

Mechanism of Action

Modulation of Platelet Signaling via Irreversible Enzyme Inhibition

Agregan acts primarily by achieving the irreversible covalent inhibition of the Cyclooxygenase-1 (COX-1) enzyme in platelets. Since platelets are anuclear and cannot replace the modified enzyme, this mechanism permanently suppresses the synthesis of the aggregation mediator, Thromboxane A2 (TXA2). This unique action influences the pathway for platelet aggregation, which inhibits the downstream signaling cascade required for platelet-to-platelet adhesion for the duration of the affected platelet's lifespan.


Suppression of Prostaglandin Cascades in Inflammatory and Central Pathways

The drug also inhibits both COX-1 and COX-2 enzymes in nucleated cells, which are mainly responsible for producing Prostaglandin E2 (PGE2) at injury sites and in the hypothalamus. This inhibition reduces the activity of mediators that contribute to the sensitization of peripheral nociceptors and alters the hypothalamic thermal set point. This results in a modulation of the nociceptive signaling pathway and a functional change in the hypothalamic thermal center, demonstrating a reversible mechanism constrained by the cellular ability to synthesize new enzyme.


Constraints of the Mechanism (Enzyme Resynthesis)

The differing rates of enzyme turnover across tissues define the duration of Agregan's effects. While the platelet action is sustained for days, the mechanisms responsible for modulating inflammation and temperature are temporary because nucleated cells can rapidly resynthesize the inhibited enzyme. This physiological constraint defines the functional duration of the mechanism in different systems of the body.

Dosage and Administration Information

How Agregan is Used: Official Administration Guidelines

Agregan, containing Acetylsalicylic Acid (ASA), is administered according to standardized administration protocols. The primary method of use is the oral route via the tablet dosage form, although the rectal route is an approved alternative method of administration when the oral route is not feasible.


Administration and Dosage Schedule

Feature Official Regulatory Instruction
Dosing Schedule The standard single dose for adults is 325 mg to 650 mg. The total dosage is not to exceed 4,000 mg (4 grams) in a 24-hour period.
Frequency Doses are repeated only as needed, maintaining an interval of 4 to 6 hours between each administration.
Duration Constraint Usage is restricted to short-term periods; for self-treatment, the medicine is generally not used for more than 10 days for pain or 3 days for fever.

Procedural and Population-Specific Conditions

Administration procedures specify that the tablet should be taken with a full glass of water or other liquid. The medicine is often administered with food or milk to aid proper intake. For specific formulations like delayed-release tablets, the medicine must be swallowed whole to ensure the intended drug release profile is maintained.

Regarding age-specific use, official labeling includes a constraint that Agregan is not for routine use in children under 12 years of age for the management of fever and pain without specific guidance. These explicit administration guidelines define a standardized protocol for the episodic application of the medicine within standardized limits.

Recent Clinical Evidence

Research Evidence Overview: How Agregan Studies Its Uses

This section will summarize the types of official research, including major clinical trials and systematic reviews, that have explored Agregan across different health contexts. It will detail the specific outcomes that researchers measured in their studies and highlight areas where the evidence is clear or still developing, doing so without making any claims of certainty, effectiveness, or giving medical advice.


Evidence for Symptomatic Relief (Pain, Fever, and Inflammation)

Official research has long examined Agregan in studies exploring patient-reported experiences of acute discomfort, such as headaches, muscle aches, and fever. These trials, relevant in trials assessing short-term or episodic symptom patterns, monitored outcomes related to physical discomfort and systemic or functional imbalance, such as measuring changes in pain intensity or body temperature over a defined time interval. Evidence regarding this acute, short-term use is extensive, but modern research often focuses on comparing its profile against newer alternatives.


Evidence for Secondary Cardiovascular Prevention

For patients who have already experienced a heart attack, stroke, or other major vascular event, research examined patterns related to the rate of recurrence. This evidence was evaluated in adult populations with established vascular disease, focusing on outcomes such as the rate of a second nonfatal heart attack, a second stroke, or vascular death, over follow-up durations that often lasted several years. Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to the rate of recurring vascular events.


Evidence for Primary Cardiovascular Prevention

Primary prevention research was studied for individuals who have not had a major cardiovascular event but have risk factors like hypertension or diabetes. Trials monitored the occurrence of a first major vascular event alongside the rate of major bleeding events. The findings were mixed across recent, large studies. While some trials reported measurements related to the rate of nonfatal heart attacks, this was associated with an observed association with an increase in major bleeding episodes in some study populations. The certainty remains low for a broad population, and data suggests patterns related to varying outcomes depending on the population.


Where Evidence Remains Uncertain or Inconsistent

The long-term balance between event patterns and the potential for bleeding are not fully established across all risk categories. Furthermore, comparative evidence is lacking that directly pits Agregan against every alternative therapy for specific indications. The results apply only to the populations studied, and evidence quality varies across studies, especially in primary prevention.

Key Studies & References

  1. Aspirin: MedlinePlus Drug Information
  2. World Health Organization Model List of Essential Medicines
  3. NICE Guideline: Hypertension in pregnancy: diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Agregan (FAQ)

Q: How quickly does Agregan start to work after you take it?

Official information indicates that when the medicine is taken orally, the antiplatelet effect, which prevents platelets from clumping together, can begin within about 60 to 90 minutes for standard doses. This timeframe can still vary depending on the individual and the specific formulation of the tablet. Information regarding the onset of action for other effects, such as pain relief, is often discussed by healthcare professionals.

Q: Why did my doctor prescribe Agregan instead of aspirin?

Agregan contains the active ingredient Acetylsalicylic Acid (ASA), which is widely recognized by its generic name, Aspirin. Therefore, Agregan and Aspirin refer to the same medicinal compound. The choice of brand name is dependent on the manufacturer and the country where the medicine is prescribed.

Q: Why do people sometimes say Agregan causes bruising easily?

Regulatory documents note that Agregan's primary function is to reduce the clotting ability of blood, which officially carries an increased risk of bleeding. Easy bruising (ecchymosis) is often a recognized physical sign that the body’s ability to clot has been affected. Reporting any unusual or excessive bruising to a healthcare provider is important.

Q: Can anxiety or nervousness be a side effect of Agregan?

Official safety data lists potential side effects that include effects on the central nervous system (CNS). While anxiety or nervousness may not be listed as a common reaction, these symptoms may be reported under the broad categories of potential adverse reactions. Any potential side effects are typically discussed with a healthcare professional.

Q: Can children or teenagers ever be prescribed Agregan?

Official guidelines state that Agregan is generally not for routine use in children under 12 for fever or pain without specific medical guidance. However, clinical data supports its use for certain conditions in pediatric patients, typically those 7 years of age and older. Dosage for younger patients is often lower and requires specific medical supervision.

Q: Is it safe to drink coffee while taking Agregan?

Regulatory warnings specifically caution against the use of chronic, heavy Alcohol while taking Agregan due to the increased risk of gastrointestinal bleeding. While there is no formal contraindication for coffee or caffeine, the medicine is generally taken with a full glass of water or food, which may help minimize potential stomach irritation.

Q: What happens if I accidentally miss a dose of Agregan?

Regulatory advice on managing a missed dose generally describes specific steps, such as when to take the dose and when to skip it. This protocol is outlined in the official patient information leaflet. The official guidance indicates that taking a double dose to compensate for a missed one should be avoided.

Q: How long do most people need to stay on Agregan therapy?

For self-treatment of short-term pain or fever, the medicine is generally not used for more than 10 days for pain or 3 days for fever, according to administration guidelines. If the medicine is used for long-term conditions, such as cardiovascular prevention, the duration of therapy is determined exclusively by a healthcare professional.

Q: Is Agregan known to affect sleep patterns?

Adverse reaction data from official sources indicate that effects such as difficulty sleeping (insomnia) or drowsiness have been reported as potential side effects. These effects are classified under the Nervous System or Psychiatric categories, though they are not always listed as common occurrences.

Q: Does Agregan interfere with any common vitamins or supplements?

Official documents list formal interactions with other prescription medications, but do not typically list every single vitamin or supplement. Regulatory guidance addresses the importance of informing a healthcare provider about all concomitant medications and supplements, including vitamins and herbs, to help screen for potential interaction risks.

Q: What is the shelf life of Agregan tablets?

The shelf life of Agregan is set by the manufacturer based on stability testing and is provided on the package's expiration date. It is essential that the medicine is stored according to regulated conditions, such as being kept in the original packaging, protected from light and moisture, and maintained at the recommended temperature.

Q: Are there generic versions of Agregan available?

Yes, Agregan contains the active ingredient Acetylsalicylic Acid (ASA), which is the generic name for Aspirin. Generic versions of this compound are widely available, and they are approved to meet the necessary quality and effectiveness standards for generic medicines.

Q: What should I do if I notice unusual bleeding while on Agregan?

Official patient guidance emphasizes that any signs of unusual or uncontrolled bleeding, excessive bruising, blood in the vomit (like coffee grounds), or black/bloody stools are considered serious warning signs. If any of these are noticed, immediate contact with a healthcare provider is appropriate.

Q: Do I need to stop taking Agregan before a minor dental procedure?

Due to the medicine's effect on bleeding, official warnings advise that patients inform their dentist or surgeon that they are taking Agregan before any procedure, including minor dental work. The decision to temporarily stop or continue the drug is a clinical one, determined by the prescribing healthcare professional on a case-by-case basis.

Q: Is it true that Agregan can sometimes cause ringing in the ears?

Yes, official labeling lists ringing in the ears (tinnitus) or loss of hearing as a potential adverse reaction, particularly at high levels of the active ingredient. Patients are informed that these symptoms may be a sign of high levels of the active ingredient, and consultation with a healthcare provider is necessary.

Q: Is Agregan safe to use if I have diabetes?

While diabetes is not listed as a formal contraindication, regulatory guidelines emphasize the need for specific risk assessment when using Agregan for primary prevention in individuals with cardiovascular risk factors, which often includes diabetes. Use of the medicine in this population often involves careful monitoring, as directed by the prescribing physician.

Q: Why do doctors recommend Agregan after a stent procedure?

Agregan is officially indicated for the secondary prevention of serious vascular events. Following a stent procedure, the medicine helps reduce the risk of a second event (such as a heart attack or stroke) by inhibiting platelet aggregation within the body's vascular system.

Q: Are there any specific warning signs I should look out for while taking Agregan?

Official patient guidance highlights several critical signs. These include: unusual or excessive bleeding, signs of a severe allergic reaction (such as swelling), ringing in the ears, and any unexpected and significant changes in stomach pain or stool appearance. All these signs are noted in official warnings as reasons to consult a healthcare provider.

Q: How does Agregan affect wound healing?

The mechanism of Agregan may affect the body’s natural response mechanisms due to its anti-inflammatory and antiplatelet activity. Monitoring and reporting any delayed or complicated wound healing to the prescribing healthcare provider is a general consideration for this class of medicine.

Q: Does Agregan interact with herbal supplements like St. John's wort?

Official drug labeling focuses on interactions with prescription medicines, but does not list every single herbal supplement. Regulatory bodies broadly state the importance of informing a healthcare provider about the use of all supplements, including herbal products like St. John's wort, to help screen for potential risks.

How should Agregan be stored and disposed of?

Official Storage and Disposal Requirements for Agregan

The storage and disposal instructions for Agregan are derived from regulatory documents, ensuring product stability and safe handling.

Storage and Handling Constraints

Category Requirement as per Official Labeling
Temperature Control Store at a controlled room temperature, typically not exceeding 25 C (77 F), or as specifically directed (e.g., refrigeration at 2 C to 8 C).
Environmental Protection Keep in the original outer packaging to protect the medication from light and moisture. Do not freeze the product.
In-Use Stability If applicable, the prepared or opened product must be used or discarded within a specified period (e.g., X days) and maintained under the required temperature conditions.
Accessibility Keep Agregan strictly out of the sight and reach of children.

Disposal Protocol

Expired or unused Agregan must be disposed of promptly according to official regulatory guidance. Patients are directed to use authorized drug take-back programs, such as those operated by pharmacies or government agencies. If a take-back program is unavailable, follow explicit at-home disposal instructions provided on the label to minimize environmental risk and accidental exposure. The primary container should be discarded only after all identifying information has been removed or concealed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Agregan found in:

A-Z Index: